雜志介紹

Annals Of Oncology雜志介紹

《Annals Of Oncology》是一本以English為主的未開放獲取國際優(yōu)秀期刊，中文名稱腫瘤學(xué)年鑒，本刊主要出版、報道醫(yī)學(xué)-ONCOLOGY領(lǐng)域的研究動態(tài)以及在該領(lǐng)域取得的各方面的經(jīng)驗和科研成果，介紹該領(lǐng)域有關(guān)本專業(yè)的最新進(jìn)展，探討行業(yè)發(fā)展的思路和方法，以促進(jìn)學(xué)術(shù)信息交流，提高行業(yè)發(fā)展。該刊已被國際權(quán)威數(shù)據(jù)庫SCIE收錄，為該領(lǐng)域相關(guān)學(xué)科的發(fā)展起到了良好的推動作用，也得到了本專業(yè)人員的廣泛認(rèn)可。該刊最新影響因子為56.7，最新CiteScore 指數(shù)為63.9。

本刊近期中國學(xué)者發(fā)表的論文主要有：

• Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial

  Author: Tang, H.; Wang, H.; Fang, Y.; Zhu, J. Y.; Yin, J.; Shen, Y. X.; Zeng, Z. C.; Xiang, D. X.; Hou, Y. Y.; Du, M.; Lian, C. H.; Zhao, Q.; Jiang, H. J.; Gong, L.; Li, Z. G.; Liu, J.; Xie, D. Y.; Li, W. F.; Chen, C.; Zheng, B.; Chen, K. N.; Dai, L.; Liao, Y. D.; Li, K.; Li, H. C.; Zhao, N. Q.; Tan, L. J.

• Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study

  Author: Rha, S. Y.; Wyrwicz, L. S.; Weber, P. E. Y.; Bai, Y.; Ryu, M. H.; Lee, J.; Rivera, F.; Alves, G. V.; Garrido, M.; Shiu, K. -k.; Fernandez, M. Gonzalez; Li, J.; Lowery, M.; Cil, T.; Cruz, F. J. S. M.; Qin, S.; Yin, L.; Bordia, S.; Bhagia, P.; Oh, D-y.

• Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study

  Author: Psyrri, A.; Fayette, J.; Harrington, K.; Gillison, M.; Ahn, M. -J.; Takahashi, S.; Weiss, J.; Machiels, J. -P.; Baxi, S.; Vasilyev, A.; Karpenko, A.; Dvorkin, M.; Hsieh, C. -Y.; Thungappa, S. C.; Segura, P. P.; Vynnychenko, I.; Haddad, R.; Kasper, S.; Mauz, P. -S.; Baker, V.; He, P.; Evans, B.; Wildsmith, S.; Olsson, R. F.; Yovine, A.; Kurland, J. F.; Morsli, N.; Seiwert, T. Y.

• Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC

  Author: Mok, T. S. K.; Lopes, G.; Cho, B. C.; Kowalski, D. M.; Kasahara, K.; Wu, Y. -l.; de Castro Jr, G.; Turna, H. Z.; Cristescu, R.; Aurora-Garg, D.; Loboda, A.; Lunceford, J.; Kobie, J.; Ayers, M.; Pietanza, M. C.; Piperdi, B.; Herbst, R. S.

英文介紹

Annals Of Oncology雜志英文介紹

Annals of Oncology, the journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology, provides rapid and efficient peer-review publications on innovative cancer treatments or translational work related to oncology and precision medicine.

Main focuses of interest include: systemic anticancer therapy (with specific interest on molecular targeted agents and new immune therapies), randomized trials (including negatives ones), top-level guidelines, and new fields currently emerging as key components of personalized medicine, such as molecular pathology, bioinformatics, modern statistics, and biotechnologies. Radiotherapy, surgery and pediatrics manuscripts can be considered if they display a clear interaction with one of the fields above or are paradigm-shifting.